Cargando…
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
Hematotoxicity after chimeric antigen receptor (CAR) T-cell therapy is associated with infection and death but management remains unclear. We report results of 31 patients receiving hematopoietic stem cell boost (HSCB; 30 autologous, 1 allogeneic) for either sustained severe neutropenia of grade 4 (...
Autores principales: | Gagelmann, Nico, Wulf, Gerald Georg, Duell, Johannes, Glass, Bertram, van Heteren, Pearl, von Tresckow, Bastian, Fischer, Monika, Penack, Olaf, Ayuk, Francis, Einsele, Herrmann, Holtick, Udo, Thomson, Julia, Dreger, Peter, Kröger, Nicolaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984300/ https://www.ncbi.nlm.nih.gov/pubmed/35696759 http://dx.doi.org/10.1182/bloodadvances.2022008042 |
Ejemplares similares
-
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
por: Ayuk, Francis, et al.
Publicado: (2023) -
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
por: Dreger, Peter, et al.
Publicado: (2022) -
P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
por: Derigs, P., et al.
Publicado: (2022) -
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
por: Schubert, Maria-Luisa, et al.
Publicado: (2023) -
P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)